Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 7.01 · 8-K

Twist Bioscience Corporation

TWSTNASDAQEQUITYCurrent

Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 18, 2026, Anthropic, PBC (“Anthropic”) published a blog post announcing that it had received data back for a multi-arm protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview, and that it had chosen Twist Bioscience Corporation (the “Company”) as one of its independent evaluators to rapidly produce at scale these AI-designed…

Filed Aug 19, 2026Accepted Aug 18, 2026, 6:15 PM EDTCIK 1581280Accession 0001581280-26-000050
Share

Company context

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by STATE STREET CORP regarding Twist Bioscience CorpNov 10, 2026
  2. SCHEDULE 13G/A - filed by FMR LLC regarding Twist Bioscience CorpNov 5, 2026
  3. 144 filingSep 21, 2026
  4. 144 filingSep 21, 2026
  5. 144 filingSep 21, 2026

Registered securities in this filing

Twist Bioscience Corporation · 8-K · Filed 2026-08-19

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
TWST
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c-1

Dimensions: Not supplied

Accession 000158128026000050 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 7.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 18, 2026, Anthropic, PBC (“Anthropic”) published a blog post announcing that it had received data back for a multi-arm protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview, and that it had chosen Twist Bioscience Corporation (the “Company”) as one of its independent evaluators to rapidly produce at scale these AI-designed proteins and test these designs for binding. The blog post is available at www.anthropic.com/research/Claude-accelerates-protein-design. Information on or accessible through Anthropic’s website is not incorporated by reference in this Current Report on Form 8-K. The information furnished in this Item 7.01 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.